[Genetics 101] Assessing Patients for Hereditary Cancer Risk with Emily Dalton, MS, CGC

• We know that not all cancer is hereditary, so how do we identify those patients who might be at risk for hereditary cancer and could benefit from genetic testing?  This course will review tools and skills used to identify at-risk patients as well as considerations for patients as they decide whether or not to pursue genetic testing. 

  

  Only the live session qualifies for CEUs but when possible, we host the recordings on our website and NSGC recommends participants to use their personal email instead of work email addresses to ensure they receive their CEU certificates.

  

  Ambry Genetics is approved as a provider for continuing education program by NSGC and ASCLS P.A.C.E ® Program.

Emily Dalton, MS, CGC | Presenter

   

Emily earned a BA in Cell and Molecular Biology from Skidmore College in Saratoga Springs, New York. She then attended the Boston University School of Medicine Genetic Counseling program, where she earned her Master’s in Genetic Counseling.  She is a current member of the BU Program Advisory Board, and has also stayed involved with the BUGC Program through course coordination, guest lecturing, and student capstone involvement.  Soon after graduating, Emily started her position as a cancer genetic counselor at Dana-Farber Cancer Institute in Boston, MA, where she had both clinical and research responsibilities.  She joined Ambry Genetics in 2013 as an Oncology Genetic Specialist, and is currently the Director of the Genetic Specialist team. 

Selvi Palaniappan, MS, CGC | Moderator

   

Selvi Palaniappan is a certified genetic counselor and Oncology Genetic Specialist at Ambry Genetics. Prior to gaining her M.S. in Genetic Counseling from University of California, Irvine, Selvi was a researcher at the Howard Hughes Medical Institute at University of Michigan. She joined Ambry after more than 20 years of working clinically at Emory University, Vanderbilt Ingram Cancer Center, and most recently, developing a cancer genetics program at Northside Hospital in Atlanta, Georgia.